Document Detail


Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
MedLine Citation:
PMID:  23944387     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Introduction: Sildenafil citrate is a potent, selective phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (PAH) and plays an important role in the management of the disease. Areas covered: In this review, we focus on the current available information on the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of sildenafil citrate in PAH through a MEDLINE literature search. Comparison of sildenafil citrate with tadalafil, another phosphodiesterase type 5 inhibitor was also performed. Expert opinion: In the last few years, considerable progress has been made in the understanding and treatment of PAH. Sildenafil citrate has multiple advantages and whether it is first-line treatment alone or in combination for the mild form of the disease, it is one of the treatments of choice. In terms of its future use, more studies are still needed to better evaluate the benefit/risk balance of sildenafil citrate in pediatric populations.
Authors:
Marie-Camille Chaumais; Swanny Perrin; Olivier Sitbon; Gérald Simonneau; Marc Humbert; David Montani
Related Documents :
1247347 - Characteristics of pleural effusions associated with pulmonary embolism.
12010297 - Lateral thoracic artery embolization in cystic fibrosis.
24969997 - Concurrence of bilateral kinking of the extracranial part of the internal carotid arter...
20173557 - Onyx embolization of arteriovenous malformations using 2 microcatheters.
19568557 - Giant true celiac artery aneurysm.
9817407 - Screening for intracranial aneurysms in patients with isolated polycystic liver disease.
Publication Detail:
Type:  Journal Article     Date:  2013-06-12
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  9     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-08-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1193-205     Citation Subset:  IM    
Affiliation:
Université Paris-Sud, Faculté de Pharmacie , Chatenay-Malabry , France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Discovery of Selective Small Molecule Type III Phosphatidylinositol 4-Kinase Alpha (PI4KIII?) Inhibi...
Next Document:  Single-particle tracking data reveal anticorrelated fractional Brownian motion in crowded fluids.